Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Radius Health stock | 15.92

Own Radius Health stock in just a few minutes.

Posted

Fact checked

Radius Health, Inc is a drug manufacturers—specialty & generic business based in the US. Radius Health shares (RDUS) are listed on the NASDAQ and all prices are listed in US Dollars. Radius Health employs 383 staff and has a trailing 12-month revenue of around USD$231.5 million.

How to buy shares in Radius Health

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Radius Health. Find the stock by name or ticker symbol: RDUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Radius Health reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$15.92, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Radius Health, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Radius Health. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Radius Health share price

Use our graph to track the performance of RDUS stocks over time.

Radius Health shares at a glance

Information last updated 2020-11-19.
Latest market close USD$15.92
52-week range USD$10.151 - USD$23.8798
50-day moving average USD$13.7357
200-day moving average USD$13.0404
Wall St. target price USD$20.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.7

Buy Radius Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Radius Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Radius Health price performance over time

Historical closes compared with the close of $15.92 from 2020-11-16

1 week (2020-11-16) 15.92
1 month (2020-10-23) 15.53%
3 months (2020-08-24) 34.80%
6 months (2020-05-22) 25.16%
1 year (2019-11-22) -31.97%
2 years (2018-11-23) 15.92
3 years (2017-11-24) -44.30%
5 years (2015-11-24) -74.03%

Radius Health financials

Revenue TTM USD$231.5 million
Gross profit TTM USD$158 million
Return on assets TTM -25.84%
Return on equity TTM 0%
Profit margin -48.61%
Book value $-0.003
Market capitalisation USD$727.1 million

TTM: trailing 12 months

Shorting Radius Health shares

There are currently 7.4 million Radius Health shares held short by investors – that's known as Radius Health's "short interest". This figure is 1.9% up from 7.3 million last month.

There are a few different ways that this level of interest in shorting Radius Health shares can be evaluated.

Radius Health's "short interest ratio" (SIR)

Radius Health's "short interest ratio" (SIR) is the quantity of Radius Health shares currently shorted divided by the average quantity of Radius Health shares traded daily (recently around 373764.39393939). Radius Health's SIR currently stands at 19.8. In other words for every 100,000 Radius Health shares traded daily on the market, roughly 19800 shares are currently held short.

However Radius Health's short interest can also be evaluated against the total number of Radius Health shares, or, against the total number of tradable Radius Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Radius Health's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Radius Health shares in existence, roughly 160 shares are currently held short) or 0.2193% of the tradable shares (for every 100,000 tradable Radius Health shares, roughly 219 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Radius Health.

Find out more about how you can short Radius Health stock.

Radius Health share dividends

We're not expecting Radius Health to pay a dividend over the next 12 months.

Have Radius Health's shares ever split?

Radius Health's shares were split on a 1:2 basis on 24 April 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Radius Health shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Radius Health shares which in turn could have impacted Radius Health's share price.

Radius Health share price volatility

Over the last 12 months, Radius Health's shares have ranged in value from as little as $10.151 up to $23.8798. A popular way to gauge a stock's volatility is its "beta".

RDUS.US volatility(beta: 1.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Radius Health's is 1.0789. This would suggest that Radius Health's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Radius Health overview

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site